Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 20/20 | 1.00 |
| ▸ | PTGIS | Q16647 | 13/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518900 | 1.00 | TBXAS1 (1.00) | TBXAS1PTGISTBXA2R | |
| SCHEMBL9035683 | 1.00 | TBXAS1 (1.00) | TBXAS1PTGISTBXA2R | |
| SCHEMBL9765942 | 0.92 | TBXAS1 (0.84) | TBXAS1PTGIS | |
| SCHEMBL9765855 | 0.86 | TBXAS1 (1.00) | TBXAS1PTGISTBXA2R | |
| SCHEMBL9765856 | 0.86 | TBXAS1 (1.00) | TBXAS1PTGISTBXA2R | |
| SCHEMBL9765895 | 0.85 | TBXAS1 (0.85) | TBXAS1PTGISTBXA2R | |
| SCHEMBL9765884 | 0.83 | TBXAS1 (1.00) | TBXAS1PTGIS | |
| SCHEMBL9765888 | 0.83 | TBXAS1 (1.00) | TBXAS1PTGIS | |
| SCHEMBL9161390 | 0.83 | TBXAS1 (1.00) | TBXAS1PTGIS | |
| SCHEMBL9765876 | 0.81 | TBXAS1 (1.00) | TBXAS1PTGIS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | claimed |
| US-6436997-B1 | Endogenous nitric oxide synthesis under conditions of low oxygen tension | NITROMED, INC. | 2002-08-20 | — | — | US | claimed |
| US-9834820-B2 | Methods for the treatment and diagnosis of bone mineral density related diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-2227560-B1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | INSERM - INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2017-10-18 | — | — | EP | disclosed |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | Universite De Paris (FR) | 2015-04-16 | — | — | US | disclosed |
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2010-11-11 | — | — | US | disclosed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284991-A1 | Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases | TBXAS1, TBXA2R, HPGDS | TBXAS1 1/4885PTGIS 5/4885TBXA2R 2/4885 |
| US-20150104437-A1 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES | TBXAS1, TBXA2R, HPGDS | TBXAS1 1/4885PTGIS 7/4885TBXA2R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.